rifampin + rifapentine + rifapentine + rifapentine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Tuberculosis
Conditions
Pulmonary Tuberculosis
Trial Timeline
Dec 1, 2008 → Dec 1, 2013
NCT ID
NCT00694629About rifampin + rifapentine + rifapentine + rifapentine
rifampin + rifapentine + rifapentine + rifapentine is a phase 2 stage product being developed by Sanofi for Pulmonary Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00694629. Target conditions include Pulmonary Tuberculosis.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Tuberculosis were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00694629 | Phase 2 | Completed |
Competing Products
20 competing products in Pulmonary Tuberculosis